Medical News Today -
14 Nov 2013 12:00
Neuroptis Biotech, the ophthalmology drug research and development specialist, announces positive results in preclinical trials of the eye-drop formulation of its ML7 product. ML7 is intended for use in the treatment of eye surface diseases, particularly dry eye. The candidate molecule, ML7, is the first in a new therapeutic class. It has the potential to bring an effective, targeted therapeutic response to the millions of people who suffer from dry eye syndromes.
Share this Article